Search

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a chronic inflammatory disease characterized by osteoarticular and cutaneous involvement as its main manifestations.[1] Inflammatory bowel disease (IBD) is a chronic inflammatory disease that mainly includes Crohn disease (CD) and ulcerative colitis (UC). Additionally, when patients develop SAPHO syndrome coexisting with IBD, we need to differentiate IBD-related arthritis and SAPHO syndrome. [Extracted from the article]

Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease that mainly involves bones, joints, and skin, characterized by sterile osteitis and neutrophilic dermatosis. SAPHO syndrome and PG may be different variations of the spectrum of autoinflammatory diseases. [Extracted from the article]

Background: Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare autoinflammatory disease; its primary manifestation includes osteoarthropathy with skin involvement. Janus kinase (JAK) inhibitors, such as tofacitinib, were used for rheumatoid arthritis; however, due to its downregulation of immune cytokines including interleukin (IL)‐6 and IL‐8, it might be effective for SAPHO patients. Case summary: We report the 1st case of mandibular‐related SAPHO syndrome treated with tofacitinib. The patient underwent mandibular resection surgery twice and postoperative pathology showed "osteomyelitis". The patient developed sclerosing osteomyelitis in the left wrist 9 months after surgery and SAPHO syndrome was diagnosed. The patient was administered nonsteroidal anti‐inflammatory drugs and corticosteroids therapy without much remission. A 3‐month tofacitinib therapy provided remission from both systemic inflammation status and peripheral osteoarticular symptoms and no significant recurrence was observed during follow‐up in this case. Conclusion: Mandibular involvement in SAPHO syndrome is easily misdiagnosed due to its rarity. Mandibular resection surgery should be applied carefully; after systemic treatment with tofacitinib, the patient had remission. We provide a successful experience for the treatment of mandibular‐related SAPHO syndrome. [ABSTRACT FROM AUTHOR]